Notice of Proposed Sale · 144
Stoke Therapeutics, Inc.
STOKNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- Stoke Therapeutics, Inc.
- Issuer CIK
- 0001623526
- SEC file number
- 001-38938
- Phone
- 7814308200
- Person for whose account securities are to be sold
- BARUCH TICHO
- Relationships to issuer
- Officer
- Street
- 45 Wiggins Ave
- City
- Bedford
- State / country code
- MA
- Postal code
- 01730
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 20,967 | 605,107.62 | 62,281,655 | 08/03/2026 | NASDAQ | Morgan Stanley Smith Barney LLC Executive Financial Services |
Broker / market maker — proposed row 1, entry 1
- Name
- Morgan Stanley Smith Barney LLC Executive Financial Services
- Street
- 1 New York Plaza
- Street (continued)
- 8th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10004
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 03/15/2026 | Restricted Stock Units | Issuer | 13,772 | N | 03/15/2026 | N/A |
| Common | 08/01/2025 | Performance Stock Units | Issuer | 7,195 | N | 08/01/2025 | N/A |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| 10b5-1 Sales for BARUCH S. TICHO | Common | 07/01/2026 | 7,228 | 236,067.93 |
| 10b5-1 Sales for BARUCH S. TICHO | Common | 06/01/2026 | 1,795 | 54,891.10 |
Seller — prior-sale row 1, entry 1
- Name
- 10b5-1 Sales for BARUCH S. TICHO
- Street
- 45 Wiggins Ave
- City
- Bedford
- State / country code
- MA
- Postal code
- 01730
Seller — prior-sale row 2, entry 1
- Name
- 10b5-1 Sales for BARUCH S. TICHO
- Street
- 45 Wiggins Ave
- City
- Bedford
- State / country code
- MA
- Postal code
- 01730
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Notice signature
- Notice date
- 08/03/2026
- Signed
- /s/ Baruch Ticho
- Plan adoption dates
- 11/19/2025
Company context
Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine. Using Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke’s first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study. Stoke’s initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Proof of concept has been demonstrated in other organs, tissues, and systems, supporting broad potential for Stoke’s proprietary approach. Stoke is headquartered in Bedford, Massachusetts. For more information, visit https://www.stoketherapeutics.com/ or follow us on LinkedIn.
Current securities
Recent company filings
- Results of Operations and Financial ConditionOct 29, 2026
- 144 filingOct 21, 2026
- SCHEDULE 13G - filed by BIOTECHNOLOGY VALUE FUND L P regarding Stoke Therapeutics, Inc.Sep 30, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsSep 25, 2026
- 4 filingAug 18, 2026